Saniya I. Valieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saniya I. Valieva has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Seda Kh. Kurbanova
Morozov Children’s City Clinical Hospital, Moscow, Russia
11 shared publications Moscow Morozov Children’s City Clinical Hospital
8 shared publications- Valerii V. Gorev
Morozovskaya Children’s Clinical Hospital
6 shared publications - Dmitry Yurievich Ovsyannikov
RUDN University (Patrice Émery Lumumba People’s Friendship University of Russia), Moscow, Russia
5 shared publications - Elena S. Zholobova
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Marina G. Kantemirova
RUDN University
4 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Consilium Medicum in Pediatrics. Consilium Medicum
- No. 3,p. 214-220
Idiopathic pulmonary hemosiderosis in children: results of a multicenter study
Background. Idiopathic pulmonary hemosiderosis (IPH) is a rare interstitial lung disease associated with recurrent diffuse alveolar hemorrhage, anemia, and the risk of pulmonary fibrosis. Aim. To describe the clinical and laboratory, computed tomographic, diagnostic, therapeutic characteristics and outcomes of children with IPH. Materials and methods. This ambispective descriptive multicenter study included 11 patients with disease onset before 18 years of age and pulmonary hemorrhage/hemosiderosis documented by bronchoscopy with bronchoalveolar lavage, cytological and/or morphological examination, after exclusion of alternative causes. Clinical history, laboratory and instrumental findings, treatment, and outcomes were evaluated. Results. The cohort included 5 boys and 6 girls. The median age at IPH onset was 6.0 [3.7; 8.6] years, the median age at diagnosis was 8.0 [4.9; 9.7] years, the median diagnostic delay was 4.9 [1.8; 22.8] months, and the median minimum hemoglobin level was 52 [38.5; 98.5] g/L (data available for 10 patients). Anemia was documented in all patients, and hemoptysis in 6/11 (55%). Signs of diffuse lung involvement on chest CT were present in all patients; ground-glass opacities and consolidation were the most common findings. Six patients required ICU care, 3 required mechanical ventilation, and 8 received red blood cell transfusions. All patients received systemic glucocorticoids; azathioprine was used in 5, rituximab in 4, and cyclophosphamide in 1 patient. Three patients died. Conclusion. IPH debuts anemia in children. The absence of hemoptysis does not exclude diffuse alveolar hemorrhage. Early computed tomography of the chest organs, bronchoscopy with bronchoalveolar lavage, the search for siderophages and the exclusion of secondary causes are the key stages of diagnosis. In severe and recurrent cases, multidisciplinary management and steroid-sparing immunosuppressive therapy are required.
- 14 October 2026
- Published by Consilium Medicum in Pediatrics. Consilium Medicum
- No. 3,p. 214-220
Open AccessIdiopathic pulmonary hemosiderosis in children: results of a multicenter study
Background. Idiopathic pulmonary hemosiderosis (IPH) is a rare interstitial lung disease associated with recurrent diffuse alveolar hemorrhage, anemia, and the risk of pulmonary fibrosis. Aim. To describe the clinical and laboratory, computed tomographic, diagnostic, therapeutic characteristics and outcomes of children with IPH. Materials and methods. This ambispective descriptive multicenter study included 11 patients with disease onset before 18 years of age and pulmonary hemorrhage/hemosiderosis documented by bronchoscopy with bronchoalveolar lavage, cytological and/or morphological examination, after exclusion of alternative causes. Clinical history, laboratory and instrumental findings, treatment, and outcomes were evaluated. Results. The cohort included 5 boys and 6 girls. The median age at IPH onset was 6.0 [3.7; 8.6] years, the median age at diagnosis was 8.0 [4.9; 9.7] years, the median diagnostic delay was 4.9 [1.8; 22.8] months, and the median minimum hemoglobin level was 52 [38.5; 98.5] g/L (data available for 10 patients). Anemia was documented in all patients, and hemoptysis in 6/11 (55%). Signs of diffuse lung involvement on chest CT were present in all patients; ground-glass opacities and consolidation were the most common findings. Six patients required ICU care, 3 required mechanical ventilation, and 8 received red blood cell transfusions. All patients received systemic glucocorticoids; azathioprine was used in 5, rituximab in 4, and cyclophosphamide in 1 patient. Three patients died. Conclusion. IPH debuts anemia in children. The absence of hemoptysis does not exclude diffuse alveolar hemorrhage. Early computed tomography of the chest organs, bronchoscopy with bronchoalveolar lavage, the search for siderophages and the exclusion of secondary causes are the key stages of diagnosis. In severe and recurrent cases, multidisciplinary management and steroid-sparing immunosuppressive therapy are required.
- 9 October 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (5)
EFFECTIVENESS AND SAFETY OF BARICITINIB IN CHILDREN WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
Baricitinib, a selective Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitor, was approved by the European Medicines Agency (EMA) in 2023 for the treatment of juvenile idiopathic arthritis (JIA) in children aged 2 years and older. Data on its use in routine clinical practice at Russian pediatric centers remain scarce. Objective: To retrospectively assess the effectiveness and safety of baricitinib in patients with JIA treated at a Russian rheumatology center. Materials and Methods: We conducted a retrospective cohort study at Morozov Children’s City Clinical Hospital. The safety analysis included 41 patients, and the effectiveness analysis included 40 patients. Follow-up lasted up to 12 months, with a median duration of 5.5 months. The primary endpoint was the change in the clinical Juvenile Arthritis Disease Activity Score based on 10 joints (cJADAS10) after 3 months of treatment (visit M3). Assessments were performed at baseline (T0) and at 3 (M3) and 6 (M6) months. Statistical analysis included nonparametric tests for paired comparisons with adjustment for multiple hypothesis testing; confidence intervals for proportions were calculated using the Wilson method. Results: The cohort included 29 girls (71%) and 12 boys (29%). The median age at treatment initiation was 11.9 years [6.2–16.1]; total follow-up was 16.0 patient-years, with a median of 5.5 months [3.2–6.2]. The cJADAS10 decreased from 13.5 [9.2–19.0] at T0 to 8.0 [4.2–11.8] at M3 (n=38; median change, –5.0 [–8.0; –2.0]; p<0.001) and to 2.0 [1.0–10.0] at M6 (n=25; median change, −9.0 [–12.0; –4.0]; p<0.001). Clinically inactive disease was documented in 27 of 36 children (75%) at M3 and in 19 of 28 (68%) at M6. Infections (≥1 episode) occurred in 13 of 41 patients (32%; at least 24 events). No serious adverse events, herpes zoster, or adverse events of special interest were recorded (0/41). Conclusion: Baricitinib treatment was associated with a marked reduction in disease activity and achievement of inactive disease in most patients. No serious adverse events or adverse events of special interest were recorded during follow-up; infections were the most common adverse events. Baricitinib may be an effective and safe treatment option for children with active JIA, although these findings require confirmation in prospective controlled studies.
- 9 October 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (5)
EFFECTIVENESS AND SAFETY OF BARICITINIB IN CHILDREN WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
Baricitinib, a selective Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitor, was approved by the European Medicines Agency (EMA) in 2023 for the treatment of juvenile idiopathic arthritis (JIA) in children aged 2 years and older. Data on its use in routine clinical practice at Russian pediatric centers remain scarce. Objective: To retrospectively assess the effectiveness and safety of baricitinib in patients with JIA treated at a Russian rheumatology center. Materials and Methods: We conducted a retrospective cohort study at Morozov Children’s City Clinical Hospital. The safety analysis included 41 patients, and the effectiveness analysis included 40 patients. Follow-up lasted up to 12 months, with a median duration of 5.5 months. The primary endpoint was the change in the clinical Juvenile Arthritis Disease Activity Score based on 10 joints (cJADAS10) after 3 months of treatment (visit M3). Assessments were performed at baseline (T0) and at 3 (M3) and 6 (M6) months. Statistical analysis included nonparametric tests for paired comparisons with adjustment for multiple hypothesis testing; confidence intervals for proportions were calculated using the Wilson method. Results: The cohort included 29 girls (71%) and 12 boys (29%). The median age at treatment initiation was 11.9 years [6.2–16.1]; total follow-up was 16.0 patient-years, with a median of 5.5 months [3.2–6.2]. The cJADAS10 decreased from 13.5 [9.2–19.0] at T0 to 8.0 [4.2–11.8] at M3 (n=38; median change, –5.0 [–8.0; –2.0]; p<0.001) and to 2.0 [1.0–10.0] at M6 (n=25; median change, −9.0 [–12.0; –4.0]; p<0.001). Clinically inactive disease was documented in 27 of 36 children (75%) at M3 and in 19 of 28 (68%) at M6. Infections (≥1 episode) occurred in 13 of 41 patients (32%; at least 24 events). No serious adverse events, herpes zoster, or adverse events of special interest were recorded (0/41). Conclusion: Baricitinib treatment was associated with a marked reduction in disease activity and achievement of inactive disease in most patients. No serious adverse events or adverse events of special interest were recorded during follow-up; infections were the most common adverse events. Baricitinib may be an effective and safe treatment option for children with active JIA, although these findings require confirmation in prospective controlled studies.
- 14 August 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (4)
RITUXIMAB USE IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE ANALYSIS OF A CLINICAL CASE SERIES
To analyze the efficacy and safety of rituximab therapy in children and adolescents with systemic lupus erythematosus (SLE). Materials and methods. A retrospective analysis of data from 21 patients with SLE (median age 14,0 [10,0; 15,0] years, 81% female) who received at least one rituximab infusion which was performed between 2016 and 2025. The dynamics of the SLEDAI activity index, organ-specific response, glucocorticosteroid dose, laboratory parameters, and the frequency of adverse events were assessed at 6 and 12 months of follow-up. Results. Rituximab therapy resulted in a statistically significant reduction in the SLEDAI index from 16,5 [11,0; 18,8] to 2,0 [2,0; 4,0] points at 6 months and to 2,0 [0,5; 2,0] points at 12 months (p<0,001). Low disease activity (SLEDAI ≤5) at 12 months was achieved in 95% of patients. A significant decrease was noted in the daily prednisolone dose from 40,0 [31,3; 50,0] to 15,0 [10,0; 20,0] mg (p=0,002) and in the weight-adjusted prednisolone dose from 1,00 [1,00; 1,00] to 0,26 [0,21; 0,32] mg/kg/day (p<0,001). Complete organ-specific response was achieved in 85,7% of patients. A significant reduction in immunoglobulin levels (IgG, IgM, IgA) was recorded (p≤0,001). Adverse events were observed in 28,6% of patients, with hypogammaglobulinemia requiring intravenous immunoglobulin being the most frequent. One fatal outcome (4,8%) occurred in a female patient with refractory SLE and multiorgan involvement. Conclusion. Rituximab demonstrated high clinical efficacy in controlling disease activity and a steroid-sparing effect in children with SLE. The safety profile of the drug was consistent with global data and requires careful monitoring for infectious complications and immunoglobulin levels.
- 14 August 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (4)
RITUXIMAB USE IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE ANALYSIS OF A CLINICAL CASE SERIES
To analyze the efficacy and safety of rituximab therapy in children and adolescents with systemic lupus erythematosus (SLE). Materials and methods. A retrospective analysis of data from 21 patients with SLE (median age 14,0 [10,0; 15,0] years, 81% female) who received at least one rituximab infusion which was performed between 2016 and 2025. The dynamics of the SLEDAI activity index, organ-specific response, glucocorticosteroid dose, laboratory parameters, and the frequency of adverse events were assessed at 6 and 12 months of follow-up. Results. Rituximab therapy resulted in a statistically significant reduction in the SLEDAI index from 16,5 [11,0; 18,8] to 2,0 [2,0; 4,0] points at 6 months and to 2,0 [0,5; 2,0] points at 12 months (p<0,001). Low disease activity (SLEDAI ≤5) at 12 months was achieved in 95% of patients. A significant decrease was noted in the daily prednisolone dose from 40,0 [31,3; 50,0] to 15,0 [10,0; 20,0] mg (p=0,002) and in the weight-adjusted prednisolone dose from 1,00 [1,00; 1,00] to 0,26 [0,21; 0,32] mg/kg/day (p<0,001). Complete organ-specific response was achieved in 85,7% of patients. A significant reduction in immunoglobulin levels (IgG, IgM, IgA) was recorded (p≤0,001). Adverse events were observed in 28,6% of patients, with hypogammaglobulinemia requiring intravenous immunoglobulin being the most frequent. One fatal outcome (4,8%) occurred in a female patient with refractory SLE and multiorgan involvement. Conclusion. Rituximab demonstrated high clinical efficacy in controlling disease activity and a steroid-sparing effect in children with SLE. The safety profile of the drug was consistent with global data and requires careful monitoring for infectious complications and immunoglobulin levels.
- 14 August 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (4)
VACCINATION COVERAGE IN CHILDREN WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: A RETROSPECTIVE COHORT STUDY
Children with immune-mediated inflammatory diseases receiving immunosuppressive therapy are at increased risk of vaccine-preventable infections. Despite the availability of international recommendations on vaccination for this patient population, data on real-world immunization coverage in the Russian pediatric population are limited. Objective: To assess vaccination coverage in children (0–17 years inclusive) with rheumatic and immune-mediated inflammatory diseases before and after diagnosis, and to identify factors associated with immunization coverage. Materials and Methods: A single-center retrospective cohort study was conducted, including 336 patients with autoimmune diseases. Results: The study included children aged 0 to 17 years, with a median age of 14.1 years [11.1; 16.4]. Females predominated: 203/336 (60.4%) vs 133/336 (39.6%). Coverage with basic vaccines ranged from 82% to 87%: DTP components – pertussis 84.2% (95% CI 79.9–87.8), diphtheria 87.2% (83.2–90.4), tetanus 85.1% (80.9–88.5); polio – 83.9% (79.6–87.5); measles, rubella, mumps – 81.2% (76.7–85.1); BCG – 81.5% (77.1–85.3); hepatitis B – 82.4% (78.0–86.1). In contrast, vaccination coverage against respiratory pathogens remained low: pneumococcal infection – 23.5% (19.3–28.3), influenza – 20.2% (16.3–24.9). Therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) showed no statistically significant association with influenza vaccination after the onset of immune-mediated inflammatory disease (OR 0.53; 95% CI 0.20–1.42; p=0.208). Conclusion: High coverage with basic National Immunization Schedule vaccines (81–87%) was found, with a substantial lag in coverage for vaccines most important for patients with potential immunosuppression. These findings support the integration of preventive vaccination into the standard patient pathway for immune-mediated inflammatory diseases, with a clear distribution of responsibility among specialists and regular verification of vaccination status.
- 14 August 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (4)
VACCINATION COVERAGE IN CHILDREN WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: A RETROSPECTIVE COHORT STUDY
Children with immune-mediated inflammatory diseases receiving immunosuppressive therapy are at increased risk of vaccine-preventable infections. Despite the availability of international recommendations on vaccination for this patient population, data on real-world immunization coverage in the Russian pediatric population are limited. Objective: To assess vaccination coverage in children (0–17 years inclusive) with rheumatic and immune-mediated inflammatory diseases before and after diagnosis, and to identify factors associated with immunization coverage. Materials and Methods: A single-center retrospective cohort study was conducted, including 336 patients with autoimmune diseases. Results: The study included children aged 0 to 17 years, with a median age of 14.1 years [11.1; 16.4]. Females predominated: 203/336 (60.4%) vs 133/336 (39.6%). Coverage with basic vaccines ranged from 82% to 87%: DTP components – pertussis 84.2% (95% CI 79.9–87.8), diphtheria 87.2% (83.2–90.4), tetanus 85.1% (80.9–88.5); polio – 83.9% (79.6–87.5); measles, rubella, mumps – 81.2% (76.7–85.1); BCG – 81.5% (77.1–85.3); hepatitis B – 82.4% (78.0–86.1). In contrast, vaccination coverage against respiratory pathogens remained low: pneumococcal infection – 23.5% (19.3–28.3), influenza – 20.2% (16.3–24.9). Therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) showed no statistically significant association with influenza vaccination after the onset of immune-mediated inflammatory disease (OR 0.53; 95% CI 0.20–1.42; p=0.208). Conclusion: High coverage with basic National Immunization Schedule vaccines (81–87%) was found, with a substantial lag in coverage for vaccines most important for patients with potential immunosuppression. These findings support the integration of preventive vaccination into the standard patient pathway for immune-mediated inflammatory diseases, with a clear distribution of responsibility among specialists and regular verification of vaccination status.
- Open Access
- 3 July 2026
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 25 (2) , 3-9
Acute rheumatic fever — a late complication of streptococcal infection: results of a 25-year study
Despite a decline in incidence, acute rheumatic fever (ARF) and recurrent ARF is a late autoimmune complication of S. pyogenes infection — remain a significant public health problem, being a cause of chronic rheumatic heart disease. Objective : to provide a clinical and epidemiological characterization and describe the outcomes of ARF based on observations of patients hospitalized between 2001 and 2025 at the Morozovskaya children’s city clinical hospital of the Moscow Department of Health. Materials and methods . We observed 113 children (60 girls, 53 boys), aged 4—17 years (median age 10 [8; 13] years), with a diagnosis of ARF (101 children) or recurrent ARF (12 children). We assessed clinical and anamnestic data, laboratory test results (antistreptolysin-O (ASO), C-reactive protein), electrocardiography (ECG), and echocardiography. Children with Sydenham's chorea underwent additional examinations. Results. A high rate of underdiagnosis of ARF was identified (63.7%). The onset of ARF most commonly occurred during the winter-spring period (61.9 %). To confirm markers of previous streptococcal infection, measuring ASO levels is more informative; an elevated ASO level (median 795 [385; 1440] IU/mL) was detected in 86.7% of children. In theclinical presentation of ARF, carditis was the predominant manifestation (81.4 %), and its frequency increased with age (p = 0,003). The mitral valve (MV) was most commonly affected (54%); combined involvement of the MV and aortic valve (AV) was observed in 34.5% of children, while isolated AV involvement occurred in 11.5 %. Arthritis was detected in 44.2% of children, with a high frequency (36/50, 72%) of atypical joint syndrome. Our study recorded a high incidence of Sydenham's chorea (56 children, 49.6%), including isolated Sydenham's chorea in 30.4%. The incidence of Sydenham's chorea decreased with age (p = 0,004). Rare manifestations of ARF — erythema marginatum and subcutaneous nodules — were observed in 14.2% and 3.4% of patients, respectively. A high incidence of chronic rheumatic heart disease (42%) was noted, with the development of rheumatic heart valve defects in 38% of cases. Conclusion . The study highlights the need for vigilance regarding ARF in patients following streptococcal infection to prevent severe outcomes such as the development of acquired heart valve defects.
- 3 July 2026
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 25 (2) , 3-9
Open AccessAcute rheumatic fever — a late complication of streptococcal infection: results of a 25-year study
Despite a decline in incidence, acute rheumatic fever (ARF) and recurrent ARF is a late autoimmune complication of S. pyogenes infection — remain a significant public health problem, being a cause of chronic rheumatic heart disease. Objective : to provide a clinical and epidemiological characterization and describe the outcomes of ARF based on observations of patients hospitalized between 2001 and 2025 at the Morozovskaya children’s city clinical hospital of the Moscow Department of Health. Materials and methods . We observed 113 children (60 girls, 53 boys), aged 4—17 years (median age 10 [8; 13] years), with a diagnosis of ARF (101 children) or recurrent ARF (12 children). We assessed clinical and anamnestic data, laboratory test results (antistreptolysin-O (ASO), C-reactive protein), electrocardiography (ECG), and echocardiography. Children with Sydenham's chorea underwent additional examinations. Results. A high rate of underdiagnosis of ARF was identified (63.7%). The onset of ARF most commonly occurred during the winter-spring period (61.9 %). To confirm markers of previous streptococcal infection, measuring ASO levels is more informative; an elevated ASO level (median 795 [385; 1440] IU/mL) was detected in 86.7% of children. In theclinical presentation of ARF, carditis was the predominant manifestation (81.4 %), and its frequency increased with age (p = 0,003). The mitral valve (MV) was most commonly affected (54%); combined involvement of the MV and aortic valve (AV) was observed in 34.5% of children, while isolated AV involvement occurred in 11.5 %. Arthritis was detected in 44.2% of children, with a high frequency (36/50, 72%) of atypical joint syndrome. Our study recorded a high incidence of Sydenham's chorea (56 children, 49.6%), including isolated Sydenham's chorea in 30.4%. The incidence of Sydenham's chorea decreased with age (p = 0,004). Rare manifestations of ARF — erythema marginatum and subcutaneous nodules — were observed in 14.2% and 3.4% of patients, respectively. A high incidence of chronic rheumatic heart disease (42%) was noted, with the development of rheumatic heart valve defects in 38% of cases. Conclusion . The study highlights the need for vigilance regarding ARF in patients following streptococcal infection to prevent severe outcomes such as the development of acquired heart valve defects.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Allogeneic transplantation of hematopoietic stem cells in congenital pyruvate kinase deficiency. Case report
Hemolytic anemia due to pyruvate kinase deficiency is a rare congenital disease caused by a defect in the glycolytic pathway. This anemia is the most common among all enzymopathies. There are various treatment methods for this disease. This article presents a clinical case of a successful allogeneic hematopoietic stem cell transplantation in a patient with pyruvate kinase deficiency.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Allogeneic transplantation of hematopoietic stem cells in congenital pyruvate kinase deficiency. Case report
Hemolytic anemia due to pyruvate kinase deficiency is a rare congenital disease caused by a defect in the glycolytic pathway. This anemia is the most common among all enzymopathies. There are various treatment methods for this disease. This article presents a clinical case of a successful allogeneic hematopoietic stem cell transplantation in a patient with pyruvate kinase deficiency.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 103-113
Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience
Objective. To assess the efficacy and safety of onasemnogene abeparvovec (OA) in children with spinal muscular atrophy (SMA) treated between 2021 and 2025 at a Moscow regional rare disease referral center (Morozov Children’s City Clinical Hospital). Material and methods. This study included 20 children with a confirmed diagnosis of 5q spinal muscular atrophy (SMA). Safety was evaluated in all 20 patients for up to 3.5 years following treatment, with adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Efficacy was analyzed in 16 patients at 8 to 37 months post-injection. Motor function was assessed using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), while general motor development was evaluated using the Hammersmith Infant Neurological Examination, Section 2 (HINE-2). Key motor milestones were compared to established World Health Organization (WHO) norms. Data was analyzed by stratifying patients into two groups: those identified through expanded newborn screening (Group 1) and those diagnosed via high-risk screening (Group 2). Results. In Group 1, the mean age at treatment initiation was 1.9 (1.4—2.8) months, with a mean weight of 4.8 (3.7—6.25) kg. In Group 2, the mean age at treatment was 14.8 (5.5—47) months, with a mean weight of 9 (6—13.7 )kg. Within one week post-OA administration, most patients (19/20) experienced clinical symptoms, including hyperthermia (Group 1: 8/9; Group 2: 10/11), increased regurgitation/vomiting (Group 1: 5/9; Group 2: 6/11), and decreased appetite/refusal to feed (Group 1: 3/9; Group 2: 9/11). These symptoms were more severe in Group 2, requiring intravenous and symptomatic therapy, nasogastric tube placement, and parenteral nutrition in some cases. Grade 1—2 thrombocytopenia (CTCAE v.5) was observed one week post-OA in three patients from Group 2. Elevated hepatic transaminases were observed in 16/20 children: Group 1 — 6/9 (66%), Group 2 — 10/11 (90%). In Group 1, all children experienced Grade 1 elevations (CTCAE v.5), while in Group 2, 6 children had Grade 1 elevations (54%), 2 had Grade 2 (18%), 1 had Grade 3 (9%), and 1 had Grade 4 (>20x ULN) (9%). Asymptomatic troponin I elevations were recorded in 6 children from Group 1 and 4 from Group 2. The median duration of prednisolone administration was 13 weeks (8—24) in Group 1 and 21 weeks (12—42) in Group 2. In Group 1, the mean CHOP INTEND score increased by 11.5 at 4 months, the HINE-2 score increased by 10.5 points at 4 months and 15.5 points at 6 months from baseline; all children achieved main motor milestones according to WHO norms. In Group 2, the mean CHOP INTEND score increased by 4 at 6 months and 7.2 points at 12 months from baseline; the HINE-2 score increased by 2.3 points at 6 months and 4.7 points at 12 months from baseline; five children improved their functional status, and 6/9 children acquired new motor skills. Conclusion. This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 103-113
Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience
Objective. To assess the efficacy and safety of onasemnogene abeparvovec (OA) in children with spinal muscular atrophy (SMA) treated between 2021 and 2025 at a Moscow regional rare disease referral center (Morozov Children’s City Clinical Hospital). Material and methods. This study included 20 children with a confirmed diagnosis of 5q spinal muscular atrophy (SMA). Safety was evaluated in all 20 patients for up to 3.5 years following treatment, with adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Efficacy was analyzed in 16 patients at 8 to 37 months post-injection. Motor function was assessed using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), while general motor development was evaluated using the Hammersmith Infant Neurological Examination, Section 2 (HINE-2). Key motor milestones were compared to established World Health Organization (WHO) norms. Data was analyzed by stratifying patients into two groups: those identified through expanded newborn screening (Group 1) and those diagnosed via high-risk screening (Group 2). Results. In Group 1, the mean age at treatment initiation was 1.9 (1.4—2.8) months, with a mean weight of 4.8 (3.7—6.25) kg. In Group 2, the mean age at treatment was 14.8 (5.5—47) months, with a mean weight of 9 (6—13.7 )kg. Within one week post-OA administration, most patients (19/20) experienced clinical symptoms, including hyperthermia (Group 1: 8/9; Group 2: 10/11), increased regurgitation/vomiting (Group 1: 5/9; Group 2: 6/11), and decreased appetite/refusal to feed (Group 1: 3/9; Group 2: 9/11). These symptoms were more severe in Group 2, requiring intravenous and symptomatic therapy, nasogastric tube placement, and parenteral nutrition in some cases. Grade 1—2 thrombocytopenia (CTCAE v.5) was observed one week post-OA in three patients from Group 2. Elevated hepatic transaminases were observed in 16/20 children: Group 1 — 6/9 (66%), Group 2 — 10/11 (90%). In Group 1, all children experienced Grade 1 elevations (CTCAE v.5), while in Group 2, 6 children had Grade 1 elevations (54%), 2 had Grade 2 (18%), 1 had Grade 3 (9%), and 1 had Grade 4 (>20x ULN) (9%). Asymptomatic troponin I elevations were recorded in 6 children from Group 1 and 4 from Group 2. The median duration of prednisolone administration was 13 weeks (8—24) in Group 1 and 21 weeks (12—42) in Group 2. In Group 1, the mean CHOP INTEND score increased by 11.5 at 4 months, the HINE-2 score increased by 10.5 points at 4 months and 15.5 points at 6 months from baseline; all children achieved main motor milestones according to WHO norms. In Group 2, the mean CHOP INTEND score increased by 4 at 6 months and 7.2 points at 12 months from baseline; the HINE-2 score increased by 2.3 points at 6 months and 4.7 points at 12 months from baseline; five children improved their functional status, and 6/9 children acquired new motor skills. Conclusion. This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.
- 9 September 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (3) , 335-349
Bronchiolitis obliterans is a fatal complication of Stevens–Johnson syndrome/toxic epidermal necrolysis in an adolescent with epilepsy treated with lamotrigine and nonsteroidal anti-inflammatory drugs: clinical and morphological comparisons
Bronchiolitis obliterans is a rare severe complication of Stevens–Johnson syndrome and toxic epidermal necrolysis. The article presents an observation of a fatal histologically confirmed bronchiolitis obliterans in a 16-year-old patient developed as a delayed complication of Stevens–Johnson syndrome after the use of lamotrigine and nonsteroidal anti-inflammatory drugs. The diagnosis of bronchiolitis obliterans was established based on the development of severe bronchoobstructive syndrome, confirmed by a study of the external respiratory function, chronic respiratory failure 2 months after Stevens–Johnson syndrome, characteristic computed tomography signs (foci of mosaic perfusion, bronchiectasis). Bronchiolitis obliterans therapy, in addition to commonly used drugs, included the janus kinase inhibitor tofacitinib. To discuss clinical observation, a systematic review of the world literature over 45 years was conducted. 43 cases of post-Stevens–Johnson syndrome/toxic epidermal necrolysis were selected from 187 publications with an analysis of the etiology, timing of onset, spirometric and radiological signs, features of therapy and course. According to the analysis, the main triggers of Stevens–Johnson syndrome/toxic epidermal necrolysis were antibiotics (50 %) and nonsteroidal anti-inflammatory drugs (40 %), infection caused by Mycoplasma pneumoniae (12 %), and less often anticonvulsants. The average age of children with bronchiolitis obliterans was 7 years, and the average age of adults was 28 years. In 50 % of cases, the manifestation of bronchiolitis obliterans occurred 1–3 months after the start of Stevens–Johnson syndrome/toxic epidermal necrolysis. Most patients (35 %) had severe bronchoobstructive syndrome, and characteristic computed tomography signs included mosaic perfusion (75 %) and bronchiectasis (49 %). Systemic (77 %) and inhaled (35 %) glucocorticosteroids, bronchodilators (63 %), and macrolide antibiotics (26 %) formed the basis of bronchiolitis obliterans therapy. Mortality in the analyzed cases reached 30 %, complete recovery was observed in only 33 %, and 35 % of patients retained persistent bronchoobstructive syndrome.
- 9 September 2025
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 22 (3) , 335-349
Bronchiolitis obliterans is a fatal complication of Stevens–Johnson syndrome/toxic epidermal necrolysis in an adolescent with epilepsy treated with lamotrigine and nonsteroidal anti-inflammatory drugs: clinical and morphological comparisons
Bronchiolitis obliterans is a rare severe complication of Stevens–Johnson syndrome and toxic epidermal necrolysis. The article presents an observation of a fatal histologically confirmed bronchiolitis obliterans in a 16-year-old patient developed as a delayed complication of Stevens–Johnson syndrome after the use of lamotrigine and nonsteroidal anti-inflammatory drugs. The diagnosis of bronchiolitis obliterans was established based on the development of severe bronchoobstructive syndrome, confirmed by a study of the external respiratory function, chronic respiratory failure 2 months after Stevens–Johnson syndrome, characteristic computed tomography signs (foci of mosaic perfusion, bronchiectasis). Bronchiolitis obliterans therapy, in addition to commonly used drugs, included the janus kinase inhibitor tofacitinib. To discuss clinical observation, a systematic review of the world literature over 45 years was conducted. 43 cases of post-Stevens–Johnson syndrome/toxic epidermal necrolysis were selected from 187 publications with an analysis of the etiology, timing of onset, spirometric and radiological signs, features of therapy and course. According to the analysis, the main triggers of Stevens–Johnson syndrome/toxic epidermal necrolysis were antibiotics (50 %) and nonsteroidal anti-inflammatory drugs (40 %), infection caused by Mycoplasma pneumoniae (12 %), and less often anticonvulsants. The average age of children with bronchiolitis obliterans was 7 years, and the average age of adults was 28 years. In 50 % of cases, the manifestation of bronchiolitis obliterans occurred 1–3 months after the start of Stevens–Johnson syndrome/toxic epidermal necrolysis. Most patients (35 %) had severe bronchoobstructive syndrome, and characteristic computed tomography signs included mosaic perfusion (75 %) and bronchiectasis (49 %). Systemic (77 %) and inhaled (35 %) glucocorticosteroids, bronchodilators (63 %), and macrolide antibiotics (26 %) formed the basis of bronchiolitis obliterans therapy. Mortality in the analyzed cases reached 30 %, complete recovery was observed in only 33 %, and 35 % of patients retained persistent bronchoobstructive syndrome.
- 28 February 2025
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 104 (1)
Clinical case report of facial neuritis, a rare manifestation of Kawasaki disease
Kawasaki disease (KD) is an acute systemic disease characterized by predominant damage to small and medium-sized arteries with the development of destructive-proliferative vasculitis, damage to the coronary (CA) and visceral arteries. In addition to the symptoms included in the diagnostic criteria for KD, other clinical manifestations are observed in the Article. Facial nerve damage in KD is a rare but serious manifestation which can be a marker for severe CA damage. Authors represent their own clinical case report of a 5-months-old male patient with late diagnosis of immunoglobulin-resistant KD with giant aneurysms of CA and facial nerve paralysis.
- 28 February 2025
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 104 (1)
Clinical case report of facial neuritis, a rare manifestation of Kawasaki disease
Kawasaki disease (KD) is an acute systemic disease characterized by predominant damage to small and medium-sized arteries with the development of destructive-proliferative vasculitis, damage to the coronary (CA) and visceral arteries. In addition to the symptoms included in the diagnostic criteria for KD, other clinical manifestations are observed in the Article. Facial nerve damage in KD is a rare but serious manifestation which can be a marker for severe CA damage. Authors represent their own clinical case report of a 5-months-old male patient with late diagnosis of immunoglobulin-resistant KD with giant aneurysms of CA and facial nerve paralysis.
- 10 December 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (6)
Monogenic autoinflammatory diseases: a bibliographical review of its modern concepts
Autoinflammatory diseases (AIDs) are a group of rare disorders characterized by recurrent episodes of inflammation with neither infectious nor autoimmune nor neoplastic trigger. The AIDs pathogenesis is based on mutations in genes that lead to uncontrolled and excessive production of proinflammatory cytokines. Authors represent current views on the pathogenesis, clinical manifestations, diagnosis and treatment of the most studied monogenic AIDs. New therapeutic approaches based on targeted blockade of key inflammatory mediators are described as well.
- 10 December 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (6)
Monogenic autoinflammatory diseases: a bibliographical review of its modern concepts
Autoinflammatory diseases (AIDs) are a group of rare disorders characterized by recurrent episodes of inflammation with neither infectious nor autoimmune nor neoplastic trigger. The AIDs pathogenesis is based on mutations in genes that lead to uncontrolled and excessive production of proinflammatory cytokines. Authors represent current views on the pathogenesis, clinical manifestations, diagnosis and treatment of the most studied monogenic AIDs. New therapeutic approaches based on targeted blockade of key inflammatory mediators are described as well.